The search for safer, more effective medicines increasingly depends on understanding how biological systems respond to disease, genetic variation, and therapeutic interventions at the molecular level. Metabolomics and lipidomics have emerged as indispensable tools in this effort, offering a window into the biochemical state of living organisms with a level of resolution that earlier analytical platforms could not match. Because metabolomics is the study of small-molecule metabolites (the downstream products of gene expression, protein activity, and environmental influence), it sits uniquely close to the phenotype of an organism, making it exceptionally sensitive to the kinds of biological changes that matter most in the drug development process. This article outlines how these technologies are applied across preclinical and clinical research, what analytical strategies underpin them, and why selecting the right analytical partner is a decisive factor in their success.
Metabolomics applications: target identification, biomarker detection, and preclinical applications
Metabolomics in drug development serves three primary functions: uncovering disease mechanisms, identifying and validating biomarkers, and evaluating pharmacological response. In target identification, unbiased discovery metabolomics (the profiling of as many metabolites as possible without prior selection) generates hypotheses about which pathways are perturbed in disease and which enzymes or receptors represent actionable nodes for therapeutic intervention. A well-documented example is the discovery of the oncometabolite 2-hydroxyglutarate in IDH1-mutant glioblastoma, identified through untargeted metabolomics and subsequently developed into both a biomarker and a drug target. This kind of discovery would be impossible through hypothesis-driven assays alone.
In preclinical research, metabolomics and drug discovery are tightly linked through the use of cellular and animal models. By knocking in or knocking out specific genes and measuring the resulting metabolite profiles using analytical techniques such as mass spectrometry, the gene-metabolome connectivity can be mapped, revealing functional consequences of genetic variants and generating translatable biomarkers that can later be monitored in clinical trials. The data produced at this stage directly informs go/no-go decisions and candidate prioritization, making early metabolomics integration a recognized strategy for reducing late-stage attrition.
A published TREM2/PLCG2 study in microglia cells illustrates this well: deletion of each gene independently produced very similar MS-derived metabolite profiles, revealing connectivity between the two proteins and informing the therapeutic rationale for activating TREM2 in Alzheimer’s disease. MS-based metabolomics also demonstrated its value in early clinical translation when plasma metabolomic changes following PI3K inhibition (first identified in preclinical models) were subsequently evaluated as pharmacodynamic biomarkers in a Phase I dose-escalation trial, confirming time- and dose-dependent effects in patients.
Biomarker discovery represents perhaps the most widely adopted application of metabolomics in drug development. Metabolite-based biomarkers identified through mass-spectrometry platforms are used for:
- Diagnosing disease or stratifying patient populations before trial enrollment
- Monitoring pharmacodynamic response and target engagement during dosing
- Assessing drug toxicity and safety through changes in metabolic pathway activity
- Supporting proof-of-concept studies in Phase I and II clinical trials
Because the metabolome integrates genomic, proteomic, and environmental inputs, it offers composite information that neither genomics nor proteomics alone can fully capture, a property that makes it especially valuable in complex, multifactorial diseases.
Lipidomics applications: lipid biomarker profiling and toxicity assessment
While metabolomics and lipidomics share a common analytical framework, lipidomics focuses specifically on lipid metabolites, a structurally diverse class encompassing sphingolipids, glycerophospholipids, glycerolipids, cholesteryl esters, and fatty acyls, among others. Their biological relevance in disease is substantial: dysregulation of lipid metabolism is causally linked to cardiovascular disease, type 2 diabetes, neurodegeneration, and several forms of cancer.
In lipidomics drug discovery, the identification of lipid biomarkers has already translated into clinical tools. Ceramide species, for instance, have been validated as predictors of cardiovascular mortality across multiple independent cohorts. The clinical assay that emerged from this work was built on a high-throughput LC-MS/MS protocol using a 96-well plate format, a workflow that enabled both the analytical precision and the sample throughput required for large-scale cohort validation, and which ultimately supported the translation of this biomarker into clinical practice. This trajectory illustrates how the combination of biological discovery and robust mass spectrometry-based analytical methodology is what actually enables lipidomics to move from research into clinical use.
For toxicity assessment specifically, lipidomics provides early signals of organ-level metabolic disruption that standard biochemical markers may miss. Changes in sphingolipid composition, lysophospholipid accumulation, or perturbations in fatty acid profiles can indicate hepatotoxicity, nephrotoxicity, or mitochondrial stress well before conventional safety endpoints become apparent. Integrating lipidomics into preclinical safety packages, therefore, enhances the predictive power of early-stage toxicology studies.
Accessing high-quality lipidomics service capabilities, with validated extraction protocols, appropriate internal standards for each lipid class, and mass spectrometry platforms calibrated for complex lipid matrices, is a practical prerequisite for generating data that will withstand regulatory scrutiny.
Targeted vs untargeted metabolomics: mass spectrometry analytical approaches
Mass spectrometry-based metabolomics and lipidomics can be approached through two fundamentally different analytical strategies (untargeted and targeted), and the choice between them is determined by the scientific question being asked and the stage of the drug development program.
1- Untargeted metabolomics
Aims to profile as many metabolites as possible in a single analytical run without prior selection. This approach uses high-resolution mass spectrometry (HRMS) instruments, typically quadrupole time-of-flight (Q-TOF) or Orbitrap platforms coupled to ultra-high performance liquid chromatography (UHPLC), and employs either data-independent acquisition (DIA) or data-dependent acquisition (DDA) methods. DDA, in particular, enables selective fragmentation of precursor ions, generating true MS/MS spectra that are essential for confident metabolite annotation via in silico tools and molecular networking workflows. The strength of this approach lies in its discovery capacity: it is well-suited to biomarker discovery, target identification, and hypothesis generation in early-phase research.
2- Targeted metabolomics
By contrast, it focuses on a predefined set of metabolites using stable isotope-labeled internal standards and triple quadrupole mass spectrometers operating in multiple reaction monitoring (MRM) mode. This approach delivers absolute quantification with high precision, reproducibility, and sensitivity, properties required when metabolites are being measured as primary or secondary endpoints in clinical trials or when regulatory-grade bioanalytical method validation is needed. Fit-for-purpose validation must be performed according to US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) guidelines, depending on the intended use of the data.
Both strategies are frequently combined in a sequential workflow: untargeted profiling identifies candidate biomarkers or metabolic signatures, which are then confirmed and quantified using targeted assays in larger cohorts. The integration of advanced platforms (such as UHPLC-MS/MS) for impurity profiling, ion-pairing-free strategies for oligonucleotide characterization, and mass spectrometry imaging for spatial metabolomics continues to expand what is analytically achievable in a modern laboratory setting.
Outsourcing metabolomics and lipidomics: how an analytical Contract Research Organization (CRO) supports your drug program
As metabolomics in drug development grows in scientific and regulatory importance, the analytical demands it places on development teams have grown correspondingly. The infrastructure required:
- Validated mass spectrometry platforms
- Experienced method development scientists
- Robust data processing pipelines
- Familiarity with regulatory expectations
Represents a significant investment that many biotech and specialty pharma organizations do not maintain in-house.
Outsourcing to a qualified analytical CRO with demonstrated expertise in metabolomics and lipidomics allows sponsors to access these capabilities on a project-appropriate basis, without incurring the overhead of building and maintaining them internally. More importantly, a CRO with deep regulatory awareness can ensure that data generated at the discovery stage is produced in ways that remain scientifically defensible as the program advances, reducing the risk of needing to repeat foundational studies due to insufficient method qualification or inadequate documentation.
At AMSbiopharma, our analytical team combines advanced mass spectrometry platforms (including UHPLC-MS/MS) with extensive experience in both targeted and untargeted metabolomics and lipidomics workflows, applied across biological matrices relevant to preclinical and clinical research. Whether your program requires early-stage biomarker discovery, fit-for-purpose assay development, lipid profiling, or regulatory-compliant quantitative analysis, we design phase-appropriate strategies that generate reliable, interpretable data in support of your development milestones.
Contact us to discuss how our metabolomics and lipidomics capabilities can strengthen the scientific foundation of your program.
References
Astarita G, Kelly RS, Lasky-Su J. Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discov Today. 2023 Oct;28(10):103751. doi: 10.1016/j.drudis.2023.103751.
Defossez E, Bourquin J, von Reuss S, Rasmann S, Glauser G. Eight key rules for successful data-dependent acquisition in mass spectrometry-based metabolomics. Mass Spectrom Rev. 2023 Jan;42(1):131-143. doi: 10.1002/mas.21715.
Lin C, Tian Q, Guo S, Xie D, Cai Y, Wang Z, Chu H, Qiu S, Tang S, Zhang A. Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification. Molecules. 2024 May 8;29(10):2198. doi: 10.3390/molecules29102198.
Meikle TG, Huynh K, Giles C, Meikle PJ. Clinical lipidomics: realizing the potential of lipid profiling. J Lipid Res. 2021;62:100127. doi: 10.1016/j.jlr.2021.100127.
